Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Assets (2021 - 2025)

ARS Pharmaceuticals' Return on Assets history spans 5 years, with the latest figure at 0.51% for Q4 2025.

  • For Q4 2025, Return on Assets fell 52.0% year-over-year to 0.51%; the TTM value through Dec 2025 reached 0.51%, down 52.0%, while the annual FY2025 figure was 0.5%, 53.0% down from the prior year.
  • Return on Assets for Q4 2025 was 0.51% at ARS Pharmaceuticals, down from 0.25% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.09% in Q3 2022 and bottomed at 0.51% in Q4 2025.
  • The 5-year median for Return on Assets is 0.07% (2025), against an average of 0.11%.
  • The largest annual shift saw Return on Assets rose 27bps in 2024 before it plummeted -52bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.09% in 2021, then tumbled by -37bps to 0.13% in 2022, then skyrocketed by 63bps to 0.05% in 2023, then surged by 113bps to 0.01% in 2024, then crashed by -8474bps to 0.51% in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Return on Assets are 0.51% (Q4 2025), 0.25% (Q3 2025), and 0.17% (Q2 2025).